Detalles de la búsqueda
1.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
2.
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
Oncologist
; 20(2): 224-6, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25568147
3.
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Lung Cancer
; 91: 70-2, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26464158
4.
Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Lung Cancer
; 96: 15-8, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27133743
5.
Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lung Cancer
; 87(2): 207-9, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25558789
6.
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Lung Cancer
; 88(3): 355-9, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882777
7.
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Lung Cancer
; 88(2): 231-4, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736571
8.
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
Lung Cancer
; 88(3): 352-4, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25851827
Resultados
1 -
8
de 8
1
Próxima >
>>